5 Top Gainers In Pharma Sector (SOLY, ARMP, VLRX...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Soliton Corp. (SOLY)

Gained 148.17% to close Tuesday's (May 28) trading at $14.22. In after-hours, the stock was up another 39.10% to $19.78.

News: The Company has received FDA clearance to market its Rapid Acoustic Pulse ("RAP") device for tattoo removal. The device is indicated as an accessory to the 1064 nm Q-Switched laser for black ink tattoo removal on the arms, legs and torso in Fitzpatrick Skin Type I-III individuals.

The potential of the RAP device is also being explored to reduce cellulite and enhance existing fat removal technologies.

We alerted our premium subscribers to SOLY on April 8, 2019 (Report titled "Making a Mark").

2. Armata Pharmaceuticals Inc. (ARMP)

Gained 31.67% to close Tuesday's trading at $4.14%.

News: The Company announced the publication of a case study involving a cystic fibrosis patient who was successfully treated for a multidrug-resistant Pseudomonas aeruginosa infection with its natural phage product, AP-PA01.

The paper, entitled "Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient," appears in the peer-reviewed journal Infection.

Pipeline:

The Company's lead product candidate, AP-SA01, is a Phase 1/2-ready asset that targets Staphylococcus aureus, including multidrug-resistant strains.

In addition, Armata is also developing and advancing a broad pipeline of proprietary synthetic phage candidates, including AP-PA01, a synthetic phage for Pseudomonas aeruginosa.

Armata has also partnered with Merck to develop proprietary synthetic phage candidates designed to target an undisclosed infectious disease agent. In addition to its work with AP-PA01, Armata is engineering its Pseudomonas aeruginosa phage to create a new, synthetic phage product, AP-PA02.

Near-term Catalyst:

The Company is slated to host bacteriophage Key Opinion Leader meeting and live webcast on Wednesday, June 26, 2019.

3. Valeritas Holdings Inc. (VLRX)

The Company is a maker of V-Go wearable insulin delivery device. V-Go won 510(k) clearance from the FDA in 2010 and CE Mark approval in the European Union in 2011.

Gained 22.94% to close Tuesday's trading at $2.84.

News: The American Diabetes Association (ADA) has included the Company's V-Go in its Standards of Medical Care in Diabetes for 2019.

The inclusion in this year's Standards of Care marks the first time such a device has been incorporated in ADA's current clinical practice recommendations.

Studies have also demonstrated that use of V-Go for insulin therapy proved to be a more cost-effective delivery option compared to multiple daily injections using syringes or pens, according to the Company.

4. Avadel Pharmaceuticals plc (AVDL)

Gained 16.23% to close Tuesday's trading at $1.79.

News:No news

Near-term Catalyst:

The Company's New Drug Application for AV001 is under Priority Review, with a decision expected on September 15, 2019.

If approved, AV001 will be the Company's fourth revenue producing Hospital Product.

5. IMAC Holdings Inc. (IMAC)

The Company owns or manages outpatient clinics that provide regenerative, orthopedic and minimally invasive procedures and therapies.

Gained 9.05% to close Tuesday's trading at $4.70.

News: The Company announced new data showing long-term post-treatment outcomes for 130 regenerative-rehabilitation patients treated at IMAC Regeneration Centers.

According to the Company, there was a 56% improvement in optimal function to 77% from 49% function; 50% improvement in quality of life to 80% from 54%; and 46% reduction in pain to 34% from 63%.